Navigation Links
Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
Date:8/30/2010

RARITAN, N.J., Aug. 30 /PRNewswire/ -- Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation. In addition, this study compared oxycodone controlled release (CR) to placebo as an active control.  

Tapentadol ER vs. Placebo

The study demonstrated that a significantly higher percentage of patients receiving tapentadol ER tablets achieved at least a 50 percent improvement in average pain intensity compared to placebo (32 percent vs. 24.3 percent, respectively; nominal p = 0.027), indicating a clinically significant improvement in pain intensity.

To measure perceived change in overall health status, patients also were asked to report their pain at Weeks 5 and 9 of the maintenance period and at the end of treatment. Results of this patient global impression of change (PGIC) analysis indicated that patients receiving tapentadol ER tablets showed statistically significant improvements compared with placebo (nominal p<0.001).

Primary endpoints for the study were the changes in average daily pain intensity from baseline (11-point numerical rating scale) over the last week of maintenance and over the study's entire 12-week maintenance period. Tapentadol ER significantly reduced average pain intensity from baseline to Week 12 of the maintenance period versus placebo (least squares mean [LSM] difference [95 percent confidence interval], -0.7 [-1.04, -0.33]), and throughout the maintenance period (-0.7 [-1.00, -0.33]).

The incidence of patients who reported at least one treatment-emergent adverse event (TEAE) was 61.1 percent for placebo and 75.9 percent for tapentadol ER. The percentages of tapentadol ER patients experiencing common TEAEs (reported by ≥10 percent in any group of the study) included
'/>"/>

SOURCE PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
2. Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
3. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
4. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
5. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
6. Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be Presented at Major Medical Meeting
7. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
8. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
9. Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
10. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
11. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 2015 Carinsurancequotesinfo.com has released a new ... cost auto insurance for flatbed trucks. , ... sometimes other vehicles. They are mainly used for commercial ... released blog post explains that by comparing multiple offers, ... and other commercial vehicles. , It is now possible ...
(Date:4/25/2015)... Islands, BWI (PRWEB) April 25, 2015 ... has celebrated three months of successfully welcoming visitors to ... 5, 2015. , As part of a major ... Providenciales airport was completely redesigned to speed up arrivals. ... the process of getting out of the airport and ...
(Date:4/25/2015)... York New York (PRWEB) April 25, 2015 ... that Dr. Jerry Blaivas has been chosen by the New ... for his contributions to medicine in the field of Urology. ... the best in his speciality, Genito-Urinary diseases. He was ... specifically in the field of urology. Not only did ...
(Date:4/25/2015)... 2015 For thirteen years, the Twin Cities ... education event in the nation! This year, on May 5th, ... US to take DI Day on the road by supporting ... CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura ... on the change by stating, "The first Twin Cities DI ...
(Date:4/24/2015)... 24, 2015 Multi Customer Discount , ... pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 gallons in Zeiter's ... program. This does not include any Dig fees, or ... per person. If someone is part of this group ... totaling approximately 2500 gallons or more, the cost would ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Secura Consultants Takes DI Day On The Road 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3
... Qiao Xing,Mobile Communication Co., Ltd. (,Qiao Xing Mobile, or ... domestic manufacturers of mobile,handsets through its subsidiary CEC Telecom ... C7000A cardiograph mobile handset., The C7000A has ... will be able to perform a basic ...
... form of breast cancer are being tested in a ... six continents -- a clinical trial that investigators hope ... This trial, dubbed ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment ... initiatives in which two large, academic breast cancer research ...
... affected by ... rare diseases, NEW YORK, Feb. ... Day will be launched on Friday 29,February...because it,s a rare day that ... Shire plc at:, http://media.medialink.com/WebNR.aspx?story=34701 ), Collectively, rare diseases aren,t ...
... Firm,s Growing Healthcare Practice, BROOKFIELD, Wis., Feb. ... human resources outsourcing company, has added,Gordon Warner to ... Services,Director., Warner brings extensive HR experience and ... Warner comes to Pinstripe from,M&I Bank in Milwaukee, ...
... 28 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ... 2008 Susquehanna Healthcare Conference will be webcast ... Investors section of the Company,s website, http://www.millennium.com ... The presentation will include an overview ...
... Idaho, Feb. 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... groups across the United States, today announced,that Ernest G. ... of the,company,s Board of Directors for personal reasons. Mr. ... company intends to immediately begin a search,to identify a ...
Cached Medicine News:Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3Health News:New study of targeted therapies for breast cancer -- model for global clinical trials 2Health News:New study of targeted therapies for breast cancer -- model for global clinical trials 3Health News:New study of targeted therapies for breast cancer -- model for global clinical trials 4Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 3Health News:Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director 2Health News:2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation 2Health News:NightHawk Radiology Holdings, Inc. Announces Board Member Departure 2
ICL manipulator with textured micro-ball tip....
0.25 mm diameter textured tip with protective guard....
... Keeler ophthalmoscopes are individually adjusted for perfect ... eye, not on paper. This, along with ... focus, ensures that whatever the patient's pupil ... largest field of view. Lithium-ion technology provides ...
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
Medicine Products: